| 注册
首页|期刊导航|中国临床药理学杂志|碳酸司维拉姆治疗维持性血液透析患者的临床研究

碳酸司维拉姆治疗维持性血液透析患者的临床研究

杨巍 程丽 陈芳 赵化南

中国临床药理学杂志2024,Vol.40Issue(8):1140-1144,5.
中国临床药理学杂志2024,Vol.40Issue(8):1140-1144,5.DOI:10.13699/j.cnki.1001-6821.2024.08.011

碳酸司维拉姆治疗维持性血液透析患者的临床研究

Clinical trial of sevelamium carbonate in the treatment of maintenance hemodialysis patients

杨巍 1程丽 1陈芳 1赵化南1

作者信息

  • 1. 亳州市中医院肾病科,安徽亳州 236800
  • 折叠

摘要

Abstract

Objective To explore the effect of sevelamer carbonate on blood phosphorus,vascular calcification,and parathyroid function in maintenance hemodialysis(MHD)patients.Methods MHD patients were selected as the research subjects and divided into treatment group and control group according to the treatment plan using a cohort method.The control group was given calcium carbonate chewable tablets orally at a dose of 1.25 g,bid,while the treatment group was given sevelamer carbonate tablets orally at a dose of 0.8 g,tid;the duration of treatment for both groups was 6 months.The clinical efficacy,blood phosphorus,blood calcium,coronary artery calcification score,parathyroid function[intact parathyroid hormone(iPTH),parathyroid volume],and levels of inflammatory factors[C-reactive protein(CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)]were compared between the two groups,and the occurrence of adverse drug reactions was recorded.Results The total effective rates of the treatment group and the control group were 92.45%(49 cases/53 cases)and 77.55%(38 cases/49 cases)respectively,showing statistically significant difference(P<0.05).After 6 months of treatment,the blood phosphorus levels of the treatment group and the control group were(1.63±0.31)and(2.07±0.36)mmol·L-1,respectively;blood calcium levels were(2.31±0.17)and(2.47±0.12)mmol·L-1,respectively;coronary artery calcification scores were 71.81±15.45 and 86.03±17.49,respectively;iPTH expression levels were(223.59±64.85)and(304.25±74.61)pg·mL-1,respectively;parathyroid volumes were(1.03±0.26)and(1.17±0.21)cm3,respectively;CRP expression levels were(5.12±1.35)and(6.59±1.66)mg·L-1,respectively;IL-6 expression levels were(16.32±2.81)and(19.84±3.62)ng·L-1,respectively;TNF-αexpression levels were(18.54±3.88)and(22.69±4.89)ng·L-1,respectively.The differences in the above indicators between the treatment group and the control group were all statistically significant(all P<0.05).The total incidence of adverse drug reactions in the treatment group and the control group were 9.43%(5 cases/53 cases)and 6.12%(3 cases/49 cases),respectively,with no statistically significant difference(P>0.05).Conclusion Sevelamer carbonate can reduce blood phosphorus levels in MHD patients,has minimal effect on blood calcium concentration,improves parathyroid function in patients,delays vascular calcification,and has good clinical application effects.

关键词

碳酸司维拉姆/维持性血液透析/血磷/甲状旁腺功能

Key words

sevelamer carbonate/maintenance hemodialysis/serum phosphorus/parathyroid function

分类

医药卫生

引用本文复制引用

杨巍,程丽,陈芳,赵化南..碳酸司维拉姆治疗维持性血液透析患者的临床研究[J].中国临床药理学杂志,2024,40(8):1140-1144,5.

中国临床药理学杂志

OA北大核心CSTPCD

1001-6821

访问量0
|
下载量0
段落导航相关论文